Evidence map›Paper›PMID 26573568›Full record

ArticleBMC cancer2015

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.

Marsha Crochiere, Trinayan Kashyap, Ori Kalid, Sharon Shechter, Boris Klebanov, William Senapedis, Jean-Richard Saint-Martin, Yosef Landesman

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

  1. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Treatment of multiple myeloma with selinexor: a review.Therapeutic advances in hematology · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Marsha CrochiereKaryopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA 02459, USA. marsha@karyopharm.com.
Trinayan KashyapKaryopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA 02459, USA. trinayan@karyopharm.com.
Ori KalidKaryopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA 02459, USA. orikalid@gmail.com.
Sharon ShechterKaryopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA 02459, USA. sshechte@gmail.com.
Boris KlebanovKaryopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA 02459, USA. boris@karyopharm.com.
William SenapedisKaryopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA 02459, USA. william@karyopharm.com.
Jean-Richard Saint-MartinKaryopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA 02459, USA. jean@karyopharm.com.
Yosef LandesmanKaryopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA 02459, USA. yosef@karyopharm.com.
Karyopharm Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExportin 1 (XPO1) is a well-characterized nuclear export protein whose expression is up-regulated in many types of cancers and functions to transport key tumor suppressor proteins (TSPs) from the nucleus. Karyopharm Therapeutics has developed a series of small-molecule Selective Inhibitor of Nuclear Export (SINE) compounds, which have been shown to block XPO1 function both in vitro and in vivo. The drug candidate, selinexor (KPT-330), is currently in Phase-II/IIb clinical trials for treatment of both hematologic and solid tumors. The present study sought to decipher the mechanisms that render cells either sensitive or resistant to treatment with SINE compounds, represented by KPT-185, an early analogue of KPT-330.

methodsUsing the human fibrosarcoma HT1080 cell line, resistance to SINE was acquired over a period of 10 months of constant incubation with increasing concentration of KPT-185. Cell viability was assayed by MTT. Immunofluorescence was used to compare nuclear export of TSPs. Fluorescence activated cell sorting (FACS), quantitative polymerase chain reaction (qPCR), and immunoblots were used to measure effects on cell cycle, gene expression, and cell death. RNA from naïve and drug treated parental and resistant cells was analyzed by Affymetrix microarrays.

resultsTreatment of HT1080 cells with gradually increasing concentrations of SINE resulted in >100 fold decrease in sensitivity to SINE cytotoxicity. Resistant cells displayed prolonged cell cycle, reduced nuclear accumulation of TSPs, and similar changes in protein expression compared to parental cells, however the magnitude of the protein expression changes were more significant in parental cells. Microarray analyses comparing parental to resistant cells indicate that a number of key signaling pathways were altered in resistant cells including expression changes in genes involved in adhesion, apoptosis, and inflammation. While the patterns of changes in transcription following drug treatment are similar in parental and resistant cells, the extent of response was more robust in the parental cells.

conclusionsThese results suggest that SINE resistance is conferred by alterations in signaling pathways downstream of XPO1 inhibition. Modulation of these pathways could potentially overcome the resistance to nuclear export inhibitors.

Indexed as

AcrylatesActive Transport, Cell NucleusAntineoplastic AgentsCell CycleCell DeathCell Line, TumorCell NucleusCell ProliferationCell SurvivalDrug Resistance, NeoplasmExportin 1 ProteinFibrosarcomaGene Expression Regulation, NeoplasticHumansKaryopherinsReceptors, Cytoplasmic and NuclearAcrylatesAntineoplastic AgentsExportin 1 ProteinKaryopherinsKPT-185Receptors, Cytoplasmic and NuclearTriazoles

Identifiers

PMID26573568
PMCPMC4647283
OpenAlexW2175632845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.